Korean antihypertensive drugs increase market share

Published: 2009-01-21 06:58:00

Updated: 2009-01-21 06:58:00

Korean-made antihypertensive drugmakers have taken up bigger share in the final quarter of last year, an industry report showed recently.

According to UBIST data, Chong Kun Dang Pharmaceutical’s Salotan (losartan) and Yuhan Corporation’s Losartan accounted for 17.8 percent and 9.8 percent of s...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK